-
Mashup Score: 8Real-World French Prospective Study on Lung Cancer Highlights Progress in NSCLC Since 2000 | Docwire News - 8 hour(s) ago
Among the 2020 cohort of patients with NSCLC, the three-year survival rate was around 35%, with a median overall survival of 17.4 months.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2FDA Approval of Tislelizumab: RATIONALE-305 Findings and Implications for Practice | Docwire News - 18 hour(s) ago
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📺 We spoke with @Sam_Cytryn of @MSKCancerCenter on last year's FDA approval of #tislelizumab and key findings from the RATIONALE-305 trial, which demonstrated the treatment's benefits of improved overall and progression-free survival. Watch now: https://t.co/LTrFZQ93Aa https://t.co/3KZBQTkiXI
-
-
Mashup Score: 4International PNH Interest Group, Max Foundation Join Forces to Improve Global PNH Care | Docwire News - 18 hour(s) ago
The new collaboration seeks to improve local PNH care in 53 countries whose health care systems have limited resources.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Clinicians, nonprofits advance #paroxysmalnocturnalhemoglobinuria care worldwide: The International PNH Interest Group (#IPIG), @themaxfndn launch collaboration to improve #PNH care in 53 countries. #Heme https://t.co/kiQP9fcAPL
-
-
Mashup Score: 0FDA Approves Subcutaneous Injection of Nivolumab, Hyaluronidase-nvhy for NSCLC, Other Solid Tumors | Docwire News - 19 hour(s) ago
The FDA approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb Company) for subcutaneous injection across most previous indications.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGULATORY UPDATE: The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection across most previously approved nivolumab indications for adults with solid tumors, including NSCLC. ➡️ Learn more: https://t.co/ptjgPdbAYn #lcsm #NSCLC #LungCancer https://t.co/s0wpbHocoi
-
-
Mashup Score: 1Automated Digital Health Program May Help Overcome Lung Cancer Screening Barriers | Docwire News - 1 day(s) ago
An automated digital health program “could overcome many system-level barriers” to lung cancer screening and increase screening rates, according to research presented at CHEST.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 An automated digital health program “could overcome many system-level barriers” to lung cancer screening and increase screening rates. ➡️ Learn more about the mPATH-Lung program: https://t.co/pGwcNgMotd #lcsm #NSCLC #SCLC https://t.co/mGwAY4L5Vc
-
-
Mashup Score: 0
Results were deduced from self-collected as well as clinician-obtained screening results.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📅 January is #CervicalCancerAwarenessMonth, and we'd like to highlight research on a new risk stratification method for #cervicalcancer from researchers out of @karolinskainst and @QMUL. 👉 Read more: https://t.co/xl7phteGba https://t.co/iIF1Icba4s
-
-
Mashup Score: 1Clinicians Search for Immune Cell–Based SCD Biomarkers, Anti-Inflammation–Based SCD Therapies | Docwire News - 2 day(s) ago
A review article describes current clinical knowledge of the role of inflammation and the activity of immune cells in SCD.
Source: docwirenews.comCategories: General Medicine News, Oncologists1Tweet-
ICYMI: A review article from @karina_t_maio and coauthors describes current understanding of #inflammation, immune cells' roles in #sicklecelldisease, the search for effective anti-inflammation-based #SCD txs. #hydroxyurea, #Heme https://t.co/tteTXwaLud
-
-
Mashup Score: 0Team Develops Model to Enhance Prediction of KRAS Mutations in Patients With NSCLC | Docwire News - 2 day(s) ago
Integrating clinical, dual-energy spectral computed tomography, and radiomics features may “enhance the prediction” of mutated KRAS in patients with lung adenocarcinoma.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📋 Integrating clinical, dual-energy spectral computed tomography, and radiomics features may enhance the prediction of KRAS mutations in patients with the lung adenocarcinoma subtype of NSCLC, according to a recent study. ➡️ Learn more: https://t.co/Ppxor2v5TT #NSCLC #lcsm https://t.co/Exk0hDagPd
-
-
Mashup Score: 1Phase 2b Study Evaluates Glecirasib in Certain Patients With KRAS-Positive NSCLC | Docwire News - 2 day(s) ago
Glecirasib has shown “promising clinical efficacy” in patients with locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) in a phase 2b study.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 Glecirasib showed an IRC-assessed ORR of 47.9% in a population of patients with locally advanced or metastatic NSCLC with the KRASG12C mutation, according to results of a phase 2b study published in @NatureMedicine. ➡️ Learn more: https://t.co/yzJOl6HNqn #NSCLC #lcsm https://t.co/zpRSW3EqCw
-
-
Mashup Score: 2New Drug for IBD Designed Using Generative AI | Docwire News - 2 day(s) ago
The early discovery of the preclinical candidate nomination took only 12 months.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
💡 Generative #AI has been used to successfully screened and nominated new drug for #IBD #irritableboweldisease treatment. 💡 Learn more here: https://t.co/7VawCLnrA3 https://t.co/kG47g661sI
-
🫁 How have NSCLC outcomes changed over the decades? 🗨️ Didier Debieuvre, MD, joined us to share insights from a real-world prospective French study on lung cancer that has been conducted every 10 years since 2000. ➡️ Watch: https://t.co/kXOhWLCT0s #lcsm #LCAM #NSCLC https://t.co/XfQ51Z0qvn